Structured Review

Santa Cruz Biotechnology anti cd5
Anti Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti cd5 - by Bioz Stars, 2023-02
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology cd5
Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cd5 - by Bioz Stars, 2023-02
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology anti cd5
NFS-25 cells cultured with DS-AF568 (red) and stained with <t>anti-CD5</t> (green) and DAPI. DS and CD5 only partially co-localize. Each panel shows four quadrants: green (upper left), red (upper right), blue (lower left), and merged (lower right) channels.
Anti Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti cd5 - by Bioz Stars, 2023-02
86/100 stars

Images

1) Product Images from "Dermatan Sulfate Is a Potential Master Regulator of IgH via Interactions with Pre-BCR, GTF2I, and BiP ER Complex in Pre-B Lymphoblasts"

Article Title: Dermatan Sulfate Is a Potential Master Regulator of IgH via Interactions with Pre-BCR, GTF2I, and BiP ER Complex in Pre-B Lymphoblasts

Journal: bioRxiv

doi: 10.1101/2021.01.18.427153

NFS-25 cells cultured with DS-AF568 (red) and stained with anti-CD5 (green) and DAPI. DS and CD5 only partially co-localize. Each panel shows four quadrants: green (upper left), red (upper right), blue (lower left), and merged (lower right) channels.
Figure Legend Snippet: NFS-25 cells cultured with DS-AF568 (red) and stained with anti-CD5 (green) and DAPI. DS and CD5 only partially co-localize. Each panel shows four quadrants: green (upper left), red (upper right), blue (lower left), and merged (lower right) channels.

Techniques Used: Cell Culture, Staining


Structured Review

Santa Cruz Biotechnology anti cd5
Components of NF-κB signaling are selectively altered in CD5hi compared to CD5lo peripheral T cells. The surface levels of <t>CD5</t> and intracellular levels of Zap70 (A), PLCγ (B), LAT (C), IκBα (D), or NF-κB (E), are shown for either CD4 (Left) or CD8 (Right) T cells. The gMFI of CD5 (F), IκBα (G), or NFκB (H) expressed by CD4 or CD8 T cells from lymph node or spleen cells, gated on live, TCR-β+ cells (n = 11 from 3 independent experiments). Statistical significance was calculated using a paired t test. ***P < 0.001; anything not marked is not statistically significant. (I) The surface levels of CD5 and CD44 are shown for CD4 (Left) or CD8 (Right) T cells. (J) The distribution of IκBα expression with other cell surface markers (CD127, CD44, CD62L, TCR-β) on polyclonal peripheral T cells from lymph node or spleen gated on live, TCR-β+ cells are shown for CD4 (Left) or CD8 (Right). CD5 CV of 66.83 ± 2.91 in CD4 CD44hi; CD5 CV of 52.98 ± 0.69 in CD4 CD44lo; CD44 CV of 65.65 ± 1.24 in CD4 CD44hi; CD44 CV of 60.80 ± 2.35 in CD4 CD44lo. (K) Western blot analysis from B6 lymphocytes sorted on 20% CD5hi and CD5lo within CD4+ and CD8+ T cell (TCR-β+) populations. Representative Western blot is shown (n = 3 from 3 independent experiments). Sorting strategy is shown in SI Appendix, Fig. S1. (L) Peripheral T cells from WT animals were sorted on 20% CD5hi and CD5lo expression as indicated in SI Appendix, Fig. S1. Cells were lysed and RNA was harvested for reverse transcription. cDNA was analyzed for expression of Actb and Nfkbia between groups. Fold-change (2ΔΔCT) of CD5hi cells compared to CD5lo cells of either CD4 or CD8 populations normalized to expression of Actb (n = 6 from 2 independent experiments).
Anti Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti cd5 - by Bioz Stars, 2023-02
86/100 stars

Images

1) Product Images from "CD5 dynamically calibrates basal NF-κB signaling in T cells during thymic development and peripheral activation"

Article Title: CD5 dynamically calibrates basal NF-κB signaling in T cells during thymic development and peripheral activation

Journal: Proceedings of the National Academy of Sciences of the United States of America

doi: 10.1073/pnas.1922525117

Components of NF-κB signaling are selectively altered in CD5hi compared to CD5lo peripheral T cells. The surface levels of CD5 and intracellular levels of Zap70 (A), PLCγ (B), LAT (C), IκBα (D), or NF-κB (E), are shown for either CD4 (Left) or CD8 (Right) T cells. The gMFI of CD5 (F), IκBα (G), or NFκB (H) expressed by CD4 or CD8 T cells from lymph node or spleen cells, gated on live, TCR-β+ cells (n = 11 from 3 independent experiments). Statistical significance was calculated using a paired t test. ***P < 0.001; anything not marked is not statistically significant. (I) The surface levels of CD5 and CD44 are shown for CD4 (Left) or CD8 (Right) T cells. (J) The distribution of IκBα expression with other cell surface markers (CD127, CD44, CD62L, TCR-β) on polyclonal peripheral T cells from lymph node or spleen gated on live, TCR-β+ cells are shown for CD4 (Left) or CD8 (Right). CD5 CV of 66.83 ± 2.91 in CD4 CD44hi; CD5 CV of 52.98 ± 0.69 in CD4 CD44lo; CD44 CV of 65.65 ± 1.24 in CD4 CD44hi; CD44 CV of 60.80 ± 2.35 in CD4 CD44lo. (K) Western blot analysis from B6 lymphocytes sorted on 20% CD5hi and CD5lo within CD4+ and CD8+ T cell (TCR-β+) populations. Representative Western blot is shown (n = 3 from 3 independent experiments). Sorting strategy is shown in SI Appendix, Fig. S1. (L) Peripheral T cells from WT animals were sorted on 20% CD5hi and CD5lo expression as indicated in SI Appendix, Fig. S1. Cells were lysed and RNA was harvested for reverse transcription. cDNA was analyzed for expression of Actb and Nfkbia between groups. Fold-change (2ΔΔCT) of CD5hi cells compared to CD5lo cells of either CD4 or CD8 populations normalized to expression of Actb (n = 6 from 2 independent experiments).
Figure Legend Snippet: Components of NF-κB signaling are selectively altered in CD5hi compared to CD5lo peripheral T cells. The surface levels of CD5 and intracellular levels of Zap70 (A), PLCγ (B), LAT (C), IκBα (D), or NF-κB (E), are shown for either CD4 (Left) or CD8 (Right) T cells. The gMFI of CD5 (F), IκBα (G), or NFκB (H) expressed by CD4 or CD8 T cells from lymph node or spleen cells, gated on live, TCR-β+ cells (n = 11 from 3 independent experiments). Statistical significance was calculated using a paired t test. ***P < 0.001; anything not marked is not statistically significant. (I) The surface levels of CD5 and CD44 are shown for CD4 (Left) or CD8 (Right) T cells. (J) The distribution of IκBα expression with other cell surface markers (CD127, CD44, CD62L, TCR-β) on polyclonal peripheral T cells from lymph node or spleen gated on live, TCR-β+ cells are shown for CD4 (Left) or CD8 (Right). CD5 CV of 66.83 ± 2.91 in CD4 CD44hi; CD5 CV of 52.98 ± 0.69 in CD4 CD44lo; CD44 CV of 65.65 ± 1.24 in CD4 CD44hi; CD44 CV of 60.80 ± 2.35 in CD4 CD44lo. (K) Western blot analysis from B6 lymphocytes sorted on 20% CD5hi and CD5lo within CD4+ and CD8+ T cell (TCR-β+) populations. Representative Western blot is shown (n = 3 from 3 independent experiments). Sorting strategy is shown in SI Appendix, Fig. S1. (L) Peripheral T cells from WT animals were sorted on 20% CD5hi and CD5lo expression as indicated in SI Appendix, Fig. S1. Cells were lysed and RNA was harvested for reverse transcription. cDNA was analyzed for expression of Actb and Nfkbia between groups. Fold-change (2ΔΔCT) of CD5hi cells compared to CD5lo cells of either CD4 or CD8 populations normalized to expression of Actb (n = 6 from 2 independent experiments).

Techniques Used: Expressing, Western Blot

Concomitant up-regulation of IκBα with developmental and peripheral modulation of CD5 levels. (A) Representative plots showing the levels of CD5 versus IκBα progressive stages of T cell development in the thymus. Thymocytes were stained for CD4, CD8, and CD69 and gated on markers listed on top of each panel (gating strategy shown in SI Appendix, Fig. S2A). DP = CD4+CD8+ and SP = single positive for either CD4 or CD8 expression as designated. (B) The CD5 and IκBα gMFI on thymocyte subsets as identified in A (n = 11 from 3 independent experiments; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons). (C) Representative peripheral expression levels of CD5 and IκBα in T cells gated by CD4+, TCR-β+, and CD25 expression, to enrich for regulatory T cells in pooled lymph node (the CD25hi population). (D) The CD5 and IκBα gMFI on CD25hi and CD25lo T cells (n = 7 from 3 independent experiments; statistical significance was calculated using paired t tests). (E) 5C.C7 TCR-tg CD4+ T cells were adoptively transferred to congenically distinct B10.A mice and challenged with MCC peptide and LPS challenge in B10.A hosts. Expression of CD5 was analyzed at varying time points after challenge on adoptively transferred TCR-tg CD4+ T cells (n = 2 to 3 from 1 independent experiment; statistical significance was calculated using Tukey’s multiple comparisons). (F) Representative flow plots gated on live, TCR-β+ and CD4+ or CD8+ cells, further subdivided by CD44 expression (gating strategy is shown in SI Appendix, Fig. S2). (G) CD5 and IκBα gMFI on CD4 or CD8 cells gated as indicated in F from lymph node or spleen (n = 11 from 3 independent experiments; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Anything not marked is not statistically significant.
Figure Legend Snippet: Concomitant up-regulation of IκBα with developmental and peripheral modulation of CD5 levels. (A) Representative plots showing the levels of CD5 versus IκBα progressive stages of T cell development in the thymus. Thymocytes were stained for CD4, CD8, and CD69 and gated on markers listed on top of each panel (gating strategy shown in SI Appendix, Fig. S2A). DP = CD4+CD8+ and SP = single positive for either CD4 or CD8 expression as designated. (B) The CD5 and IκBα gMFI on thymocyte subsets as identified in A (n = 11 from 3 independent experiments; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons). (C) Representative peripheral expression levels of CD5 and IκBα in T cells gated by CD4+, TCR-β+, and CD25 expression, to enrich for regulatory T cells in pooled lymph node (the CD25hi population). (D) The CD5 and IκBα gMFI on CD25hi and CD25lo T cells (n = 7 from 3 independent experiments; statistical significance was calculated using paired t tests). (E) 5C.C7 TCR-tg CD4+ T cells were adoptively transferred to congenically distinct B10.A mice and challenged with MCC peptide and LPS challenge in B10.A hosts. Expression of CD5 was analyzed at varying time points after challenge on adoptively transferred TCR-tg CD4+ T cells (n = 2 to 3 from 1 independent experiment; statistical significance was calculated using Tukey’s multiple comparisons). (F) Representative flow plots gated on live, TCR-β+ and CD4+ or CD8+ cells, further subdivided by CD44 expression (gating strategy is shown in SI Appendix, Fig. S2). (G) CD5 and IκBα gMFI on CD4 or CD8 cells gated as indicated in F from lymph node or spleen (n = 11 from 3 independent experiments; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Anything not marked is not statistically significant.

Techniques Used: Staining, Expressing

CD5-IκBα correlation is independent of SHP-1 and has a saturable level of IκBα up-regulation. (A) Western blot analysis of thymocytes from WT and SHP-1–KO animals (n = 1 from 1 independent experiment). (B) Flow cytometry analysis of WT and SHP-1–KO splenocytes (n = 1 from 1 independent experiment). (C) CD5 and IκBα gMFI in WT and SHP-1–KO splenocytes (n = 1 from 1 independent experiment). (D) CD5 and IκBα gMFI of peripheral T cells after 24 h ex vivo culture in the presence or absence of varying concentrations CX4945 (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (E) WT and CD5 transgenic (CD5-Tg) thymocytes were harvested and analyzed for expression of CD5 and IκBα. Representative flow plots are shown. (F) CD5 and IκBα gMFI on peripheral CD4 and CD8 T cells from WT and CD5-Tg animals (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (G) WT and CD5-Tg lymphocytes were harvested from pooled lymph nodes and grouped into bins by CD5 expression as detailed in SI Appendix, Fig. S5. Frequency of population in each bin is displayed for CD4 and CD8 peripheral T cells (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (H) Lymphocytes from SMARTA CD4+ TCR-Tg mice were isolated and stimulated ex vivo with TCR-αβ KO antigen presenting cells and cognate peptide for the indicated time points. Cells were harvested and analyzed by flow cytometry. CD5 and IκBα gMFI of SMARTA CD4+ TCR-Tg T cells (n = 1 from 1 independent experiment). (I) BW-5147 cells were transduced with empty or CD5 retroviral vector. Cells were rested for 5 d after transduction and then analyzed by flow cytometry. Representative flow plots are shown. (J) CD5 and IκBα gMFI on retrovirally transduced BW-5147 cells (n = 4 from 3 independent experiments; statistical significance was calculated using one-way ANOVA with Tukey’s multiple comparisons test). **P < 0.01. (K) 3T3 cells were transduced with empty retroviral vector or with CD5 retroviral vector. Cells were rested for 48 h after transduction and then analyzed by flow cytometry. (n = 1 from 1 independent experiment).
Figure Legend Snippet: CD5-IκBα correlation is independent of SHP-1 and has a saturable level of IκBα up-regulation. (A) Western blot analysis of thymocytes from WT and SHP-1–KO animals (n = 1 from 1 independent experiment). (B) Flow cytometry analysis of WT and SHP-1–KO splenocytes (n = 1 from 1 independent experiment). (C) CD5 and IκBα gMFI in WT and SHP-1–KO splenocytes (n = 1 from 1 independent experiment). (D) CD5 and IκBα gMFI of peripheral T cells after 24 h ex vivo culture in the presence or absence of varying concentrations CX4945 (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (E) WT and CD5 transgenic (CD5-Tg) thymocytes were harvested and analyzed for expression of CD5 and IκBα. Representative flow plots are shown. (F) CD5 and IκBα gMFI on peripheral CD4 and CD8 T cells from WT and CD5-Tg animals (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (G) WT and CD5-Tg lymphocytes were harvested from pooled lymph nodes and grouped into bins by CD5 expression as detailed in SI Appendix, Fig. S5. Frequency of population in each bin is displayed for CD4 and CD8 peripheral T cells (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (H) Lymphocytes from SMARTA CD4+ TCR-Tg mice were isolated and stimulated ex vivo with TCR-αβ KO antigen presenting cells and cognate peptide for the indicated time points. Cells were harvested and analyzed by flow cytometry. CD5 and IκBα gMFI of SMARTA CD4+ TCR-Tg T cells (n = 1 from 1 independent experiment). (I) BW-5147 cells were transduced with empty or CD5 retroviral vector. Cells were rested for 5 d after transduction and then analyzed by flow cytometry. Representative flow plots are shown. (J) CD5 and IκBα gMFI on retrovirally transduced BW-5147 cells (n = 4 from 3 independent experiments; statistical significance was calculated using one-way ANOVA with Tukey’s multiple comparisons test). **P < 0.01. (K) 3T3 cells were transduced with empty retroviral vector or with CD5 retroviral vector. Cells were rested for 48 h after transduction and then analyzed by flow cytometry. (n = 1 from 1 independent experiment).

Techniques Used: Western Blot, Flow Cytometry, Ex Vivo, Transgenic Assay, Expressing, Isolation, Transduction, Plasmid Preparation

The surface expression of CD5 is necessary for maintaining heterogenous levels of IκBα in T cells. (A) A similar gating strategy as in Fig. 2A was used to examine different thymocyte subsets in WT (Upper) or CD5-KO (Lower) mice and representative flow plots are shown. (B) The gMFI of CD5 and IκBα on thymocyte populations as gated in Fig. 2A from WT or CD5-KO mice (n = 3 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (C) Peripheral live, TCR-β+ CD4, or CD8 T cells from the pooled lymph nodes of WT or CD5-KO mice were analyzed for CD5 and IκBα expression and a representative set of flow plots are shown. (D) The gMFI of CD5 and IκBα gMFI in peripheral CD4 or CD8 T cells gated as indicated above from lymph nodes, respectively (n = 3 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (E) Representative flow plots of thymocytes and peripheral T cells isolated from lymph nodes of CD5-floxed mice with CAG-CreERT2 transgene (CD5 inducible knockouts; CD5-iKO) after treatment with tamoxifen for 5 d. Histograms of CD5 expression are shown. (F) The expression of CD5 and IκBα in thymocytes of either wild-type (WT, Upper) or CD5-floxed mice with CAG-CreERT2 transgene (CD5-iKO, Lower) after treatment with tamoxifen for 5 d. Representative flow plots are shown. (G) CD5 and IκBα gMFI on thymocytes as gated in Fig. 2A from WT or CD5-iKO mice (n = 2 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (H) The expression of CD5 and IκBα in peripheral T cells in either WT or CD5-iKO mice after treatment with tamoxifen for 5 d. Representative flow plots are shown. (I) CD5 and IκBα of peripheral CD4 or CD8 T cells gated as indicated above from lymph nodes of WT or CD5-iKO mice (n = 2 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test).
Figure Legend Snippet: The surface expression of CD5 is necessary for maintaining heterogenous levels of IκBα in T cells. (A) A similar gating strategy as in Fig. 2A was used to examine different thymocyte subsets in WT (Upper) or CD5-KO (Lower) mice and representative flow plots are shown. (B) The gMFI of CD5 and IκBα on thymocyte populations as gated in Fig. 2A from WT or CD5-KO mice (n = 3 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (C) Peripheral live, TCR-β+ CD4, or CD8 T cells from the pooled lymph nodes of WT or CD5-KO mice were analyzed for CD5 and IκBα expression and a representative set of flow plots are shown. (D) The gMFI of CD5 and IκBα gMFI in peripheral CD4 or CD8 T cells gated as indicated above from lymph nodes, respectively (n = 3 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (E) Representative flow plots of thymocytes and peripheral T cells isolated from lymph nodes of CD5-floxed mice with CAG-CreERT2 transgene (CD5 inducible knockouts; CD5-iKO) after treatment with tamoxifen for 5 d. Histograms of CD5 expression are shown. (F) The expression of CD5 and IκBα in thymocytes of either wild-type (WT, Upper) or CD5-floxed mice with CAG-CreERT2 transgene (CD5-iKO, Lower) after treatment with tamoxifen for 5 d. Representative flow plots are shown. (G) CD5 and IκBα gMFI on thymocytes as gated in Fig. 2A from WT or CD5-iKO mice (n = 2 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (H) The expression of CD5 and IκBα in peripheral T cells in either WT or CD5-iKO mice after treatment with tamoxifen for 5 d. Representative flow plots are shown. (I) CD5 and IκBα of peripheral CD4 or CD8 T cells gated as indicated above from lymph nodes of WT or CD5-iKO mice (n = 2 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test).

Techniques Used: Expressing, Isolation

CD5 expression confers thymocyte survival advantage. (A) Thymocytes from B6 mice were cultured ex vivo for 24 h. Cells were stained and gated as in SI Appendix, Fig. S2A, together with Annexin V and 7AAD to assess cell death. The populations were grouped based on top and bottom 20% of CD5 expression within each population. Representative flow plots are shown. (B) The frequencies of Annexin V+ cells within the top and bottom 20% of CD5 expressers are shown (n = 4 from 1 experiment is shown and n = 3 from a second independent experiment). (C) Thymocytes from B6 mice were cultured ex vivo for 15 h with or without varying Bay 11-7082 doses. Cells were stained and gated as in SI Appendix, Fig. S2, together with Annexin V and 7AAD to assess cell death. Representative flow plots are shown for the double-positive CD69hi population. (D) The frequencies of Annexin V+ cells within the top and bottom 20% of CD5 expressers of the double-positive CD69hi population are shown (n = 3 from 1 independent experiment). *P < 0.05; **P < 0.01; ***P < 0.001; anything not marked is not statistically significant.
Figure Legend Snippet: CD5 expression confers thymocyte survival advantage. (A) Thymocytes from B6 mice were cultured ex vivo for 24 h. Cells were stained and gated as in SI Appendix, Fig. S2A, together with Annexin V and 7AAD to assess cell death. The populations were grouped based on top and bottom 20% of CD5 expression within each population. Representative flow plots are shown. (B) The frequencies of Annexin V+ cells within the top and bottom 20% of CD5 expressers are shown (n = 4 from 1 experiment is shown and n = 3 from a second independent experiment). (C) Thymocytes from B6 mice were cultured ex vivo for 15 h with or without varying Bay 11-7082 doses. Cells were stained and gated as in SI Appendix, Fig. S2, together with Annexin V and 7AAD to assess cell death. Representative flow plots are shown for the double-positive CD69hi population. (D) The frequencies of Annexin V+ cells within the top and bottom 20% of CD5 expressers of the double-positive CD69hi population are shown (n = 3 from 1 independent experiment). *P < 0.05; **P < 0.01; ***P < 0.001; anything not marked is not statistically significant.

Techniques Used: Expressing, Cell Culture, Ex Vivo, Staining


Structured Review

Santa Cruz Biotechnology anti cd5
Components of NF-κB signaling are selectively altered in CD5hi compared to CD5lo peripheral T cells. The surface levels of <t>CD5</t> and intracellular levels of Zap70 (A), PLCγ (B), LAT (C), IκBα (D), or NF-κB (E), are shown for either CD4 (Left) or CD8 (Right) T cells. The gMFI of CD5 (F), IκBα (G), or NFκB (H) expressed by CD4 or CD8 T cells from lymph node or spleen cells, gated on live, TCR-β+ cells (n = 11 from 3 independent experiments). Statistical significance was calculated using a paired t test. ***P < 0.001; anything not marked is not statistically significant. (I) The surface levels of CD5 and CD44 are shown for CD4 (Left) or CD8 (Right) T cells. (J) The distribution of IκBα expression with other cell surface markers (CD127, CD44, CD62L, TCR-β) on polyclonal peripheral T cells from lymph node or spleen gated on live, TCR-β+ cells are shown for CD4 (Left) or CD8 (Right). CD5 CV of 66.83 ± 2.91 in CD4 CD44hi; CD5 CV of 52.98 ± 0.69 in CD4 CD44lo; CD44 CV of 65.65 ± 1.24 in CD4 CD44hi; CD44 CV of 60.80 ± 2.35 in CD4 CD44lo. (K) Western blot analysis from B6 lymphocytes sorted on 20% CD5hi and CD5lo within CD4+ and CD8+ T cell (TCR-β+) populations. Representative Western blot is shown (n = 3 from 3 independent experiments). Sorting strategy is shown in SI Appendix, Fig. S1. (L) Peripheral T cells from WT animals were sorted on 20% CD5hi and CD5lo expression as indicated in SI Appendix, Fig. S1. Cells were lysed and RNA was harvested for reverse transcription. cDNA was analyzed for expression of Actb and Nfkbia between groups. Fold-change (2ΔΔCT) of CD5hi cells compared to CD5lo cells of either CD4 or CD8 populations normalized to expression of Actb (n = 6 from 2 independent experiments).
Anti Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti cd5 - by Bioz Stars, 2023-02
86/100 stars

Images

1) Product Images from "CD5 dynamically calibrates basal NF-κB signaling in T cells during thymic development and peripheral activation"

Article Title: CD5 dynamically calibrates basal NF-κB signaling in T cells during thymic development and peripheral activation

Journal: Proceedings of the National Academy of Sciences of the United States of America

doi: 10.1073/pnas.1922525117

Components of NF-κB signaling are selectively altered in CD5hi compared to CD5lo peripheral T cells. The surface levels of CD5 and intracellular levels of Zap70 (A), PLCγ (B), LAT (C), IκBα (D), or NF-κB (E), are shown for either CD4 (Left) or CD8 (Right) T cells. The gMFI of CD5 (F), IκBα (G), or NFκB (H) expressed by CD4 or CD8 T cells from lymph node or spleen cells, gated on live, TCR-β+ cells (n = 11 from 3 independent experiments). Statistical significance was calculated using a paired t test. ***P < 0.001; anything not marked is not statistically significant. (I) The surface levels of CD5 and CD44 are shown for CD4 (Left) or CD8 (Right) T cells. (J) The distribution of IκBα expression with other cell surface markers (CD127, CD44, CD62L, TCR-β) on polyclonal peripheral T cells from lymph node or spleen gated on live, TCR-β+ cells are shown for CD4 (Left) or CD8 (Right). CD5 CV of 66.83 ± 2.91 in CD4 CD44hi; CD5 CV of 52.98 ± 0.69 in CD4 CD44lo; CD44 CV of 65.65 ± 1.24 in CD4 CD44hi; CD44 CV of 60.80 ± 2.35 in CD4 CD44lo. (K) Western blot analysis from B6 lymphocytes sorted on 20% CD5hi and CD5lo within CD4+ and CD8+ T cell (TCR-β+) populations. Representative Western blot is shown (n = 3 from 3 independent experiments). Sorting strategy is shown in SI Appendix, Fig. S1. (L) Peripheral T cells from WT animals were sorted on 20% CD5hi and CD5lo expression as indicated in SI Appendix, Fig. S1. Cells were lysed and RNA was harvested for reverse transcription. cDNA was analyzed for expression of Actb and Nfkbia between groups. Fold-change (2ΔΔCT) of CD5hi cells compared to CD5lo cells of either CD4 or CD8 populations normalized to expression of Actb (n = 6 from 2 independent experiments).
Figure Legend Snippet: Components of NF-κB signaling are selectively altered in CD5hi compared to CD5lo peripheral T cells. The surface levels of CD5 and intracellular levels of Zap70 (A), PLCγ (B), LAT (C), IκBα (D), or NF-κB (E), are shown for either CD4 (Left) or CD8 (Right) T cells. The gMFI of CD5 (F), IκBα (G), or NFκB (H) expressed by CD4 or CD8 T cells from lymph node or spleen cells, gated on live, TCR-β+ cells (n = 11 from 3 independent experiments). Statistical significance was calculated using a paired t test. ***P < 0.001; anything not marked is not statistically significant. (I) The surface levels of CD5 and CD44 are shown for CD4 (Left) or CD8 (Right) T cells. (J) The distribution of IκBα expression with other cell surface markers (CD127, CD44, CD62L, TCR-β) on polyclonal peripheral T cells from lymph node or spleen gated on live, TCR-β+ cells are shown for CD4 (Left) or CD8 (Right). CD5 CV of 66.83 ± 2.91 in CD4 CD44hi; CD5 CV of 52.98 ± 0.69 in CD4 CD44lo; CD44 CV of 65.65 ± 1.24 in CD4 CD44hi; CD44 CV of 60.80 ± 2.35 in CD4 CD44lo. (K) Western blot analysis from B6 lymphocytes sorted on 20% CD5hi and CD5lo within CD4+ and CD8+ T cell (TCR-β+) populations. Representative Western blot is shown (n = 3 from 3 independent experiments). Sorting strategy is shown in SI Appendix, Fig. S1. (L) Peripheral T cells from WT animals were sorted on 20% CD5hi and CD5lo expression as indicated in SI Appendix, Fig. S1. Cells were lysed and RNA was harvested for reverse transcription. cDNA was analyzed for expression of Actb and Nfkbia between groups. Fold-change (2ΔΔCT) of CD5hi cells compared to CD5lo cells of either CD4 or CD8 populations normalized to expression of Actb (n = 6 from 2 independent experiments).

Techniques Used: Expressing, Western Blot

Concomitant up-regulation of IκBα with developmental and peripheral modulation of CD5 levels. (A) Representative plots showing the levels of CD5 versus IκBα progressive stages of T cell development in the thymus. Thymocytes were stained for CD4, CD8, and CD69 and gated on markers listed on top of each panel (gating strategy shown in SI Appendix, Fig. S2A). DP = CD4+CD8+ and SP = single positive for either CD4 or CD8 expression as designated. (B) The CD5 and IκBα gMFI on thymocyte subsets as identified in A (n = 11 from 3 independent experiments; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons). (C) Representative peripheral expression levels of CD5 and IκBα in T cells gated by CD4+, TCR-β+, and CD25 expression, to enrich for regulatory T cells in pooled lymph node (the CD25hi population). (D) The CD5 and IκBα gMFI on CD25hi and CD25lo T cells (n = 7 from 3 independent experiments; statistical significance was calculated using paired t tests). (E) 5C.C7 TCR-tg CD4+ T cells were adoptively transferred to congenically distinct B10.A mice and challenged with MCC peptide and LPS challenge in B10.A hosts. Expression of CD5 was analyzed at varying time points after challenge on adoptively transferred TCR-tg CD4+ T cells (n = 2 to 3 from 1 independent experiment; statistical significance was calculated using Tukey’s multiple comparisons). (F) Representative flow plots gated on live, TCR-β+ and CD4+ or CD8+ cells, further subdivided by CD44 expression (gating strategy is shown in SI Appendix, Fig. S2). (G) CD5 and IκBα gMFI on CD4 or CD8 cells gated as indicated in F from lymph node or spleen (n = 11 from 3 independent experiments; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Anything not marked is not statistically significant.
Figure Legend Snippet: Concomitant up-regulation of IκBα with developmental and peripheral modulation of CD5 levels. (A) Representative plots showing the levels of CD5 versus IκBα progressive stages of T cell development in the thymus. Thymocytes were stained for CD4, CD8, and CD69 and gated on markers listed on top of each panel (gating strategy shown in SI Appendix, Fig. S2A). DP = CD4+CD8+ and SP = single positive for either CD4 or CD8 expression as designated. (B) The CD5 and IκBα gMFI on thymocyte subsets as identified in A (n = 11 from 3 independent experiments; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons). (C) Representative peripheral expression levels of CD5 and IκBα in T cells gated by CD4+, TCR-β+, and CD25 expression, to enrich for regulatory T cells in pooled lymph node (the CD25hi population). (D) The CD5 and IκBα gMFI on CD25hi and CD25lo T cells (n = 7 from 3 independent experiments; statistical significance was calculated using paired t tests). (E) 5C.C7 TCR-tg CD4+ T cells were adoptively transferred to congenically distinct B10.A mice and challenged with MCC peptide and LPS challenge in B10.A hosts. Expression of CD5 was analyzed at varying time points after challenge on adoptively transferred TCR-tg CD4+ T cells (n = 2 to 3 from 1 independent experiment; statistical significance was calculated using Tukey’s multiple comparisons). (F) Representative flow plots gated on live, TCR-β+ and CD4+ or CD8+ cells, further subdivided by CD44 expression (gating strategy is shown in SI Appendix, Fig. S2). (G) CD5 and IκBα gMFI on CD4 or CD8 cells gated as indicated in F from lymph node or spleen (n = 11 from 3 independent experiments; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Anything not marked is not statistically significant.

Techniques Used: Staining, Expressing

CD5-IκBα correlation is independent of SHP-1 and has a saturable level of IκBα up-regulation. (A) Western blot analysis of thymocytes from WT and SHP-1–KO animals (n = 1 from 1 independent experiment). (B) Flow cytometry analysis of WT and SHP-1–KO splenocytes (n = 1 from 1 independent experiment). (C) CD5 and IκBα gMFI in WT and SHP-1–KO splenocytes (n = 1 from 1 independent experiment). (D) CD5 and IκBα gMFI of peripheral T cells after 24 h ex vivo culture in the presence or absence of varying concentrations CX4945 (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (E) WT and CD5 transgenic (CD5-Tg) thymocytes were harvested and analyzed for expression of CD5 and IκBα. Representative flow plots are shown. (F) CD5 and IκBα gMFI on peripheral CD4 and CD8 T cells from WT and CD5-Tg animals (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (G) WT and CD5-Tg lymphocytes were harvested from pooled lymph nodes and grouped into bins by CD5 expression as detailed in SI Appendix, Fig. S5. Frequency of population in each bin is displayed for CD4 and CD8 peripheral T cells (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (H) Lymphocytes from SMARTA CD4+ TCR-Tg mice were isolated and stimulated ex vivo with TCR-αβ KO antigen presenting cells and cognate peptide for the indicated time points. Cells were harvested and analyzed by flow cytometry. CD5 and IκBα gMFI of SMARTA CD4+ TCR-Tg T cells (n = 1 from 1 independent experiment). (I) BW-5147 cells were transduced with empty or CD5 retroviral vector. Cells were rested for 5 d after transduction and then analyzed by flow cytometry. Representative flow plots are shown. (J) CD5 and IκBα gMFI on retrovirally transduced BW-5147 cells (n = 4 from 3 independent experiments; statistical significance was calculated using one-way ANOVA with Tukey’s multiple comparisons test). **P < 0.01. (K) 3T3 cells were transduced with empty retroviral vector or with CD5 retroviral vector. Cells were rested for 48 h after transduction and then analyzed by flow cytometry. (n = 1 from 1 independent experiment).
Figure Legend Snippet: CD5-IκBα correlation is independent of SHP-1 and has a saturable level of IκBα up-regulation. (A) Western blot analysis of thymocytes from WT and SHP-1–KO animals (n = 1 from 1 independent experiment). (B) Flow cytometry analysis of WT and SHP-1–KO splenocytes (n = 1 from 1 independent experiment). (C) CD5 and IκBα gMFI in WT and SHP-1–KO splenocytes (n = 1 from 1 independent experiment). (D) CD5 and IκBα gMFI of peripheral T cells after 24 h ex vivo culture in the presence or absence of varying concentrations CX4945 (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (E) WT and CD5 transgenic (CD5-Tg) thymocytes were harvested and analyzed for expression of CD5 and IκBα. Representative flow plots are shown. (F) CD5 and IκBα gMFI on peripheral CD4 and CD8 T cells from WT and CD5-Tg animals (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (G) WT and CD5-Tg lymphocytes were harvested from pooled lymph nodes and grouped into bins by CD5 expression as detailed in SI Appendix, Fig. S5. Frequency of population in each bin is displayed for CD4 and CD8 peripheral T cells (n = 3 from 1 independent experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (H) Lymphocytes from SMARTA CD4+ TCR-Tg mice were isolated and stimulated ex vivo with TCR-αβ KO antigen presenting cells and cognate peptide for the indicated time points. Cells were harvested and analyzed by flow cytometry. CD5 and IκBα gMFI of SMARTA CD4+ TCR-Tg T cells (n = 1 from 1 independent experiment). (I) BW-5147 cells were transduced with empty or CD5 retroviral vector. Cells were rested for 5 d after transduction and then analyzed by flow cytometry. Representative flow plots are shown. (J) CD5 and IκBα gMFI on retrovirally transduced BW-5147 cells (n = 4 from 3 independent experiments; statistical significance was calculated using one-way ANOVA with Tukey’s multiple comparisons test). **P < 0.01. (K) 3T3 cells were transduced with empty retroviral vector or with CD5 retroviral vector. Cells were rested for 48 h after transduction and then analyzed by flow cytometry. (n = 1 from 1 independent experiment).

Techniques Used: Western Blot, Flow Cytometry, Ex Vivo, Transgenic Assay, Expressing, Isolation, Transduction, Plasmid Preparation

The surface expression of CD5 is necessary for maintaining heterogenous levels of IκBα in T cells. (A) A similar gating strategy as in Fig. 2A was used to examine different thymocyte subsets in WT (Upper) or CD5-KO (Lower) mice and representative flow plots are shown. (B) The gMFI of CD5 and IκBα on thymocyte populations as gated in Fig. 2A from WT or CD5-KO mice (n = 3 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (C) Peripheral live, TCR-β+ CD4, or CD8 T cells from the pooled lymph nodes of WT or CD5-KO mice were analyzed for CD5 and IκBα expression and a representative set of flow plots are shown. (D) The gMFI of CD5 and IκBα gMFI in peripheral CD4 or CD8 T cells gated as indicated above from lymph nodes, respectively (n = 3 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (E) Representative flow plots of thymocytes and peripheral T cells isolated from lymph nodes of CD5-floxed mice with CAG-CreERT2 transgene (CD5 inducible knockouts; CD5-iKO) after treatment with tamoxifen for 5 d. Histograms of CD5 expression are shown. (F) The expression of CD5 and IκBα in thymocytes of either wild-type (WT, Upper) or CD5-floxed mice with CAG-CreERT2 transgene (CD5-iKO, Lower) after treatment with tamoxifen for 5 d. Representative flow plots are shown. (G) CD5 and IκBα gMFI on thymocytes as gated in Fig. 2A from WT or CD5-iKO mice (n = 2 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (H) The expression of CD5 and IκBα in peripheral T cells in either WT or CD5-iKO mice after treatment with tamoxifen for 5 d. Representative flow plots are shown. (I) CD5 and IκBα of peripheral CD4 or CD8 T cells gated as indicated above from lymph nodes of WT or CD5-iKO mice (n = 2 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test).
Figure Legend Snippet: The surface expression of CD5 is necessary for maintaining heterogenous levels of IκBα in T cells. (A) A similar gating strategy as in Fig. 2A was used to examine different thymocyte subsets in WT (Upper) or CD5-KO (Lower) mice and representative flow plots are shown. (B) The gMFI of CD5 and IκBα on thymocyte populations as gated in Fig. 2A from WT or CD5-KO mice (n = 3 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (C) Peripheral live, TCR-β+ CD4, or CD8 T cells from the pooled lymph nodes of WT or CD5-KO mice were analyzed for CD5 and IκBα expression and a representative set of flow plots are shown. (D) The gMFI of CD5 and IκBα gMFI in peripheral CD4 or CD8 T cells gated as indicated above from lymph nodes, respectively (n = 3 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (E) Representative flow plots of thymocytes and peripheral T cells isolated from lymph nodes of CD5-floxed mice with CAG-CreERT2 transgene (CD5 inducible knockouts; CD5-iKO) after treatment with tamoxifen for 5 d. Histograms of CD5 expression are shown. (F) The expression of CD5 and IκBα in thymocytes of either wild-type (WT, Upper) or CD5-floxed mice with CAG-CreERT2 transgene (CD5-iKO, Lower) after treatment with tamoxifen for 5 d. Representative flow plots are shown. (G) CD5 and IκBα gMFI on thymocytes as gated in Fig. 2A from WT or CD5-iKO mice (n = 2 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test). (H) The expression of CD5 and IκBα in peripheral T cells in either WT or CD5-iKO mice after treatment with tamoxifen for 5 d. Representative flow plots are shown. (I) CD5 and IκBα of peripheral CD4 or CD8 T cells gated as indicated above from lymph nodes of WT or CD5-iKO mice (n = 2 to 5 from 1 experiment; statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test).

Techniques Used: Expressing, Isolation

CD5 expression confers thymocyte survival advantage. (A) Thymocytes from B6 mice were cultured ex vivo for 24 h. Cells were stained and gated as in SI Appendix, Fig. S2A, together with Annexin V and 7AAD to assess cell death. The populations were grouped based on top and bottom 20% of CD5 expression within each population. Representative flow plots are shown. (B) The frequencies of Annexin V+ cells within the top and bottom 20% of CD5 expressers are shown (n = 4 from 1 experiment is shown and n = 3 from a second independent experiment). (C) Thymocytes from B6 mice were cultured ex vivo for 15 h with or without varying Bay 11-7082 doses. Cells were stained and gated as in SI Appendix, Fig. S2, together with Annexin V and 7AAD to assess cell death. Representative flow plots are shown for the double-positive CD69hi population. (D) The frequencies of Annexin V+ cells within the top and bottom 20% of CD5 expressers of the double-positive CD69hi population are shown (n = 3 from 1 independent experiment). *P < 0.05; **P < 0.01; ***P < 0.001; anything not marked is not statistically significant.
Figure Legend Snippet: CD5 expression confers thymocyte survival advantage. (A) Thymocytes from B6 mice were cultured ex vivo for 24 h. Cells were stained and gated as in SI Appendix, Fig. S2A, together with Annexin V and 7AAD to assess cell death. The populations were grouped based on top and bottom 20% of CD5 expression within each population. Representative flow plots are shown. (B) The frequencies of Annexin V+ cells within the top and bottom 20% of CD5 expressers are shown (n = 4 from 1 experiment is shown and n = 3 from a second independent experiment). (C) Thymocytes from B6 mice were cultured ex vivo for 15 h with or without varying Bay 11-7082 doses. Cells were stained and gated as in SI Appendix, Fig. S2, together with Annexin V and 7AAD to assess cell death. Representative flow plots are shown for the double-positive CD69hi population. (D) The frequencies of Annexin V+ cells within the top and bottom 20% of CD5 expressers of the double-positive CD69hi population are shown (n = 3 from 1 independent experiment). *P < 0.05; **P < 0.01; ***P < 0.001; anything not marked is not statistically significant.

Techniques Used: Expressing, Cell Culture, Ex Vivo, Staining


Structured Review

Santa Cruz Biotechnology cd5 pe
Infiltrating T cells (CD3, <t>CD5),</t> B cells (CD 20) and macrophages [CD68], are increased in the renal cortical interstitium of the angiotensin-infused rats (Ang II group n = 7), and reduced by the administration of BBG (Ang II + BBG n = 7). CD45 antigen is a leukocyte common antigen predominantly expressed in lymphocytes. White bars (□) Sham; Black bars (■) AngII; and grey bars ( ■ ) Ang II + BBG. * p < 0.001 vs. sham, ** p < 0.05 vs. Ang II. Ang II = angiotensin II; BBG = brilliant blue G.
Cd5 Pe, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5 pe/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cd5 pe - by Bioz Stars, 2023-02
86/100 stars

Images

1) Product Images from "The Role of P2X7 Purinergic Receptors in the Renal Inflammation Associated with Angiotensin II-Induced Hypertension"

Article Title: The Role of P2X7 Purinergic Receptors in the Renal Inflammation Associated with Angiotensin II-Induced Hypertension

Journal: International Journal of Molecular Sciences

doi: 10.3390/ijms21114041

Infiltrating T cells (CD3, CD5), B cells (CD 20) and macrophages [CD68], are increased in the renal cortical interstitium of the angiotensin-infused rats (Ang II group n = 7), and reduced by the administration of BBG (Ang II + BBG n = 7). CD45 antigen is a leukocyte common antigen predominantly expressed in lymphocytes. White bars (□) Sham; Black bars (■) AngII; and grey bars ( ■ ) Ang II + BBG. * p < 0.001 vs. sham, ** p < 0.05 vs. Ang II. Ang II = angiotensin II; BBG = brilliant blue G.
Figure Legend Snippet: Infiltrating T cells (CD3, CD5), B cells (CD 20) and macrophages [CD68], are increased in the renal cortical interstitium of the angiotensin-infused rats (Ang II group n = 7), and reduced by the administration of BBG (Ang II + BBG n = 7). CD45 antigen is a leukocyte common antigen predominantly expressed in lymphocytes. White bars (□) Sham; Black bars (■) AngII; and grey bars ( ■ ) Ang II + BBG. * p < 0.001 vs. sham, ** p < 0.05 vs. Ang II. Ang II = angiotensin II; BBG = brilliant blue G.

Techniques Used:

P2X7 receptors (second column) in the infiltrating T cells of Ang II group co-localize with cluster differentiation (CD, first column) antigens in T cells (CD 3 positive cells), B cells (CD5 and CD20 positive cells), macrophages (CD68 positive cells) and leukocyte common antigen CD45, predominantly expressed in T lymphocytes.
Figure Legend Snippet: P2X7 receptors (second column) in the infiltrating T cells of Ang II group co-localize with cluster differentiation (CD, first column) antigens in T cells (CD 3 positive cells), B cells (CD5 and CD20 positive cells), macrophages (CD68 positive cells) and leukocyte common antigen CD45, predominantly expressed in T lymphocytes.

Techniques Used:


Structured Review

Santa Cruz Biotechnology cd5
Clinical and phenotypic characteristics of patients with PD‐L1 + and PD‐L1 − IVLBCL
Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cd5 - by Bioz Stars, 2023-02
86/100 stars

Images

1) Product Images from "PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy"

Article Title: PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy

Journal: Cancer Medicine

doi: 10.1002/cam4.3104

Clinical and phenotypic characteristics of patients with PD‐L1 + and PD‐L1 − IVLBCL
Figure Legend Snippet: Clinical and phenotypic characteristics of patients with PD‐L1 + and PD‐L1 − IVLBCL

Techniques Used: Variant Assay

Histological and immunohistochemical features of intravascular large B‐cell lymphoma. Large tumor cells were identified in (A) the capillaries of skin (HE × 400) and (B) bone marrow (HE × 400). Immunohistochemically, these large cells were uniformly positive for (C) CD20 (anti‐CD20 antibody, ×400), (D) 35% (12/34) showed positivity for PD‐L1 (anti PD‐L1 antibody, ×400), and (E) 38% (10/26) showed positivity for CD5 (anti‐CD5 antibody, ×400)
Figure Legend Snippet: Histological and immunohistochemical features of intravascular large B‐cell lymphoma. Large tumor cells were identified in (A) the capillaries of skin (HE × 400) and (B) bone marrow (HE × 400). Immunohistochemically, these large cells were uniformly positive for (C) CD20 (anti‐CD20 antibody, ×400), (D) 35% (12/34) showed positivity for PD‐L1 (anti PD‐L1 antibody, ×400), and (E) 38% (10/26) showed positivity for CD5 (anti‐CD5 antibody, ×400)

Techniques Used: Immunohistochemical staining

Clinical and phenotypic characteristics of patients with PD‐L1 + IVLBCL and PD‐L1 + eDLBCL
Figure Legend Snippet: Clinical and phenotypic characteristics of patients with PD‐L1 + IVLBCL and PD‐L1 + eDLBCL

Techniques Used:


Structured Review

Santa Cruz Biotechnology cd5
Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cd5 - by Bioz Stars, 2023-02
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology cd5
Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cd5 - by Bioz Stars, 2023-02
86/100 stars

Images


Structured Review

Santa Cruz Biotechnology anti cd5
Antigens expressed in Neu-medullocytes as B cells: IgG, <t>CD5,</t> IgM, and MHC class II. ( I ) Reconfirmation of the expression of IgG on X-NANA-stained cells using F(ab′) 2 fragment of anti-mouse IgG as detected by confocal microscopy. The thymus from a C57BL/6 mouse (male, 6 W) was used. ( A ) X-NANA-stained; ( B ) FITC-anti-mouse IgG; ( C and D ) merged ( A and B ). ( D and E ) enlarged area enclosed by a white square in ( C ) and its DIC (differential interference contrast) image, respectively. ( F ) DIC image including the areas from ( A – C ) (white square) and ( D , E ) (black square). Scale bars in ( A , D and F ) indicate 50 (for A – C ), 20 (for D and E ) and 100 µm (for F ), respectively. ( II ) Other antigens expressed on X-NANA stained cells. The thymus sections from C57BL/6 mice were used for ( A – C ) (male, 6 W). The thymus sections from AKR mice (haplotype k) were used for ( D – F ) (male, 8 W) and for ( G – I ) (female, 5 W). ( A , D and G ) X-NANA stained; ( B ) FITC-anti-CD5 stained; ( C ) merged ( A and B) ; ( E ) FITC-anti-MHC class II (anti I-A k ) stained; ( F ) merged ( D and E ); ( H ) R.R.-anti-IgM stained; ( I ) merged ( G and H ). The scale bars (μm) indicate 20 in A (for A – C ), 20 in D (for D – F ), and 50 in G (for G – I ).
Anti Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti cd5 - by Bioz Stars, 2023-02
86/100 stars

Images

1) Product Images from "Neu-medullocytes, sialidase-positive B cells in the thymus, express autoimmune regulator (AIRE)"

Article Title: Neu-medullocytes, sialidase-positive B cells in the thymus, express autoimmune regulator (AIRE)

Journal: Scientific Reports

doi: 10.1038/s41598-018-37225-y

Antigens expressed in Neu-medullocytes as B cells: IgG, CD5, IgM, and MHC class II. ( I ) Reconfirmation of the expression of IgG on X-NANA-stained cells using F(ab′) 2 fragment of anti-mouse IgG as detected by confocal microscopy. The thymus from a C57BL/6 mouse (male, 6 W) was used. ( A ) X-NANA-stained; ( B ) FITC-anti-mouse IgG; ( C and D ) merged ( A and B ). ( D and E ) enlarged area enclosed by a white square in ( C ) and its DIC (differential interference contrast) image, respectively. ( F ) DIC image including the areas from ( A – C ) (white square) and ( D , E ) (black square). Scale bars in ( A , D and F ) indicate 50 (for A – C ), 20 (for D and E ) and 100 µm (for F ), respectively. ( II ) Other antigens expressed on X-NANA stained cells. The thymus sections from C57BL/6 mice were used for ( A – C ) (male, 6 W). The thymus sections from AKR mice (haplotype k) were used for ( D – F ) (male, 8 W) and for ( G – I ) (female, 5 W). ( A , D and G ) X-NANA stained; ( B ) FITC-anti-CD5 stained; ( C ) merged ( A and B) ; ( E ) FITC-anti-MHC class II (anti I-A k ) stained; ( F ) merged ( D and E ); ( H ) R.R.-anti-IgM stained; ( I ) merged ( G and H ). The scale bars (μm) indicate 20 in A (for A – C ), 20 in D (for D – F ), and 50 in G (for G – I ).
Figure Legend Snippet: Antigens expressed in Neu-medullocytes as B cells: IgG, CD5, IgM, and MHC class II. ( I ) Reconfirmation of the expression of IgG on X-NANA-stained cells using F(ab′) 2 fragment of anti-mouse IgG as detected by confocal microscopy. The thymus from a C57BL/6 mouse (male, 6 W) was used. ( A ) X-NANA-stained; ( B ) FITC-anti-mouse IgG; ( C and D ) merged ( A and B ). ( D and E ) enlarged area enclosed by a white square in ( C ) and its DIC (differential interference contrast) image, respectively. ( F ) DIC image including the areas from ( A – C ) (white square) and ( D , E ) (black square). Scale bars in ( A , D and F ) indicate 50 (for A – C ), 20 (for D and E ) and 100 µm (for F ), respectively. ( II ) Other antigens expressed on X-NANA stained cells. The thymus sections from C57BL/6 mice were used for ( A – C ) (male, 6 W). The thymus sections from AKR mice (haplotype k) were used for ( D – F ) (male, 8 W) and for ( G – I ) (female, 5 W). ( A , D and G ) X-NANA stained; ( B ) FITC-anti-CD5 stained; ( C ) merged ( A and B) ; ( E ) FITC-anti-MHC class II (anti I-A k ) stained; ( F ) merged ( D and E ); ( H ) R.R.-anti-IgM stained; ( I ) merged ( G and H ). The scale bars (μm) indicate 20 in A (for A – C ), 20 in D (for D – F ), and 50 in G (for G – I ).

Techniques Used: Expressing, Staining, Confocal Microscopy

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Santa Cruz Biotechnology anti cd5
    Anti Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd5/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cd5 - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology cd5
    Cd5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd5/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd5 - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology cd5 pe
    Infiltrating T cells (CD3, <t>CD5),</t> B cells (CD 20) and macrophages [CD68], are increased in the renal cortical interstitium of the angiotensin-infused rats (Ang II group n = 7), and reduced by the administration of BBG (Ang II + BBG n = 7). CD45 antigen is a leukocyte common antigen predominantly expressed in lymphocytes. White bars (□) Sham; Black bars (■) AngII; and grey bars ( ■ ) Ang II + BBG. * p < 0.001 vs. sham, ** p < 0.05 vs. Ang II. Ang II = angiotensin II; BBG = brilliant blue G.
    Cd5 Pe, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd5 pe/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd5 pe - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    Image Search Results


    Infiltrating T cells (CD3, CD5), B cells (CD 20) and macrophages [CD68], are increased in the renal cortical interstitium of the angiotensin-infused rats (Ang II group n = 7), and reduced by the administration of BBG (Ang II + BBG n = 7). CD45 antigen is a leukocyte common antigen predominantly expressed in lymphocytes. White bars (□) Sham; Black bars (■) AngII; and grey bars ( ■ ) Ang II + BBG. * p < 0.001 vs. sham, ** p < 0.05 vs. Ang II. Ang II = angiotensin II; BBG = brilliant blue G.

    Journal: International Journal of Molecular Sciences

    Article Title: The Role of P2X7 Purinergic Receptors in the Renal Inflammation Associated with Angiotensin II-Induced Hypertension

    doi: 10.3390/ijms21114041

    Figure Lengend Snippet: Infiltrating T cells (CD3, CD5), B cells (CD 20) and macrophages [CD68], are increased in the renal cortical interstitium of the angiotensin-infused rats (Ang II group n = 7), and reduced by the administration of BBG (Ang II + BBG n = 7). CD45 antigen is a leukocyte common antigen predominantly expressed in lymphocytes. White bars (□) Sham; Black bars (■) AngII; and grey bars ( ■ ) Ang II + BBG. * p < 0.001 vs. sham, ** p < 0.05 vs. Ang II. Ang II = angiotensin II; BBG = brilliant blue G.

    Article Snippet: Tissues were co-stained with phycoerythrin (PE)-labeled antibodies, anti-CD3-PE, -CD5-PE, -CD20-PE, -CD45-PE, or -CD68-PE antibodies (Cat #: sc-20047 PE, sc-1180 PE, sc-393894 PE, sc-1178 PE, sc-20060 PE, mouse monoclonal antibodies Santa Cruz Biotechnology, Dallas TX, USA), for localization of receptors expressed in inflammatory cells.

    Techniques:

    P2X7 receptors (second column) in the infiltrating T cells of Ang II group co-localize with cluster differentiation (CD, first column) antigens in T cells (CD 3 positive cells), B cells (CD5 and CD20 positive cells), macrophages (CD68 positive cells) and leukocyte common antigen CD45, predominantly expressed in T lymphocytes.

    Journal: International Journal of Molecular Sciences

    Article Title: The Role of P2X7 Purinergic Receptors in the Renal Inflammation Associated with Angiotensin II-Induced Hypertension

    doi: 10.3390/ijms21114041

    Figure Lengend Snippet: P2X7 receptors (second column) in the infiltrating T cells of Ang II group co-localize with cluster differentiation (CD, first column) antigens in T cells (CD 3 positive cells), B cells (CD5 and CD20 positive cells), macrophages (CD68 positive cells) and leukocyte common antigen CD45, predominantly expressed in T lymphocytes.

    Article Snippet: Tissues were co-stained with phycoerythrin (PE)-labeled antibodies, anti-CD3-PE, -CD5-PE, -CD20-PE, -CD45-PE, or -CD68-PE antibodies (Cat #: sc-20047 PE, sc-1180 PE, sc-393894 PE, sc-1178 PE, sc-20060 PE, mouse monoclonal antibodies Santa Cruz Biotechnology, Dallas TX, USA), for localization of receptors expressed in inflammatory cells.

    Techniques: